Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Assets Average (2016 - 2025)

ImmunityBio (IBRX) has disclosed Assets Average for 11 consecutive years, with $510.4 million as the latest value for Q4 2025.

  • Quarterly Assets Average rose 36.57% to $510.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $510.4 million through Dec 2025, up 36.57% year-over-year, with the annual reading at $442.4 million for FY2025, 0.29% changed from the prior year.
  • Assets Average for Q4 2025 was $510.4 million at ImmunityBio, up from $460.5 million in the prior quarter.
  • The five-year high for Assets Average was $510.4 million in Q4 2025, with the low at $215.4 million in Q1 2021.
  • Average Assets Average over 5 years is $365.6 million, with a median of $355.7 million recorded in 2022.
  • The sharpest move saw Assets Average surged 99.28% in 2022, then decreased 24.13% in 2025.
  • Over 5 years, Assets Average stood at $341.7 million in 2021, then rose by 4.68% to $357.6 million in 2022, then skyrocketed by 30.98% to $468.4 million in 2023, then decreased by 20.21% to $373.8 million in 2024, then skyrocketed by 36.57% to $510.4 million in 2025.
  • According to Business Quant data, Assets Average over the past three periods came in at $510.4 million, $460.5 million, and $352.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.